218 related articles for article (PubMed ID: 20830810)
21. Inducible nitric oxide synthase subserves cholinergic vasodilation in retina.
Berra A; Ganzinelli S; Saravia M; Borda E; Sterin-Borda L
Vis Neurosci; 2005; 22(3):371-7. PubMed ID: 16079011
[TBL] [Abstract][Full Text] [Related]
22. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group.
Barber AJ; Antonetti DA; Gardner TW
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3561-8. PubMed ID: 11006253
[TBL] [Abstract][Full Text] [Related]
23. Captopril alleviates oxidative damage in diabetic retinopathy.
Gao X; Liu K; Hu C; Chen K; Jiang Z
Life Sci; 2022 Feb; 290():120246. PubMed ID: 34953892
[TBL] [Abstract][Full Text] [Related]
24. Glial reactivity, an early feature of diabetic retinopathy.
Rungger-Brändle E; Dosso AA; Leuenberger PM
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1971-80. PubMed ID: 10845624
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological blockade of the P2X7 receptor reverses retinal damage in a rat model of type 1 diabetes.
Clapp C; Diaz-Lezama N; Adan-Castro E; Ramirez-Hernandez G; Moreno-Carranza B; Sarti AC; Falzoni S; Solini A; Di Virgilio F
Acta Diabetol; 2019 Sep; 56(9):1031-1036. PubMed ID: 30982154
[TBL] [Abstract][Full Text] [Related]
26. Retinal glial cell immunoreactivity and neuronal cell changes in rats with STZ-induced diabetes.
Agardh E; Bruun A; Agardh CD
Curr Eye Res; 2001 Oct; 23(4):276-84. PubMed ID: 11852429
[TBL] [Abstract][Full Text] [Related]
27. Protective effects of the neuropeptide PACAP in diabetic retinopathy.
Szabadfi K; Atlasz T; Kiss P; Reglodi D; Szabo A; Kovacs K; Szalontai B; Setalo G; Banki E; Csanaky K; Tamas A; Gabriel R
Cell Tissue Res; 2012 Apr; 348(1):37-46. PubMed ID: 22350850
[TBL] [Abstract][Full Text] [Related]
28. Effects of phlorizin on diabetic retinopathy according to isobaric tags for relative and absolute quantification-based proteomics in db/db mice.
Zhang SY; Li BY; Li XL; Cheng M; Cai Q; Yu F; Wang WD; Tan M; Yan G; Hu SL; Gao HQ
Mol Vis; 2013; 19():812-21. PubMed ID: 23592918
[TBL] [Abstract][Full Text] [Related]
29. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
[TBL] [Abstract][Full Text] [Related]
30. Functional hyperemia and mechanisms of neurovascular coupling in the retinal vasculature.
Newman EA
J Cereb Blood Flow Metab; 2013 Nov; 33(11):1685-95. PubMed ID: 23963372
[TBL] [Abstract][Full Text] [Related]
31. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.
Kern TS; Miller CM; Du Y; Zheng L; Mohr S; Ball SL; Kim M; Jamison JA; Bingaman DP
Diabetes; 2007 Feb; 56(2):373-9. PubMed ID: 17259381
[TBL] [Abstract][Full Text] [Related]
32. Aquaporin 4 knockdown exacerbates streptozotocin-induced diabetic retinopathy through aggravating inflammatory response.
Cui B; Sun JH; Xiang FF; Liu L; Li WJ
Exp Eye Res; 2012 May; 98():37-43. PubMed ID: 22449442
[TBL] [Abstract][Full Text] [Related]
33. Erythropoietin protects retinal neurons and glial cells in early-stage streptozotocin-induced diabetic rats.
Zhu B; Wang W; Gu Q; Xu X
Exp Eye Res; 2008 Feb; 86(2):375-82. PubMed ID: 18191124
[TBL] [Abstract][Full Text] [Related]
34. Low-intensity far-red light inhibits early lesions that contribute to diabetic retinopathy: in vivo and in vitro.
Tang J; Du Y; Lee CA; Talahalli R; Eells JT; Kern TS
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3681-90. PubMed ID: 23557732
[TBL] [Abstract][Full Text] [Related]
35. Diabetic eNOS-knockout mice develop accelerated retinopathy.
Li Q; Verma A; Han PY; Nakagawa T; Johnson RJ; Grant MB; Campbell-Thompson M; Jarajapu YP; Lei B; Hauswirth WW
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5240-6. PubMed ID: 20435587
[TBL] [Abstract][Full Text] [Related]
36. Inducible nitric oxide synthase inhibitors abolished histological protection by late ischemic preconditioning in rat retina.
Sakamoto K; Yonoki Y; Kubota Y; Kuwagata M; Saito M; Nakahara T; Ishii K
Exp Eye Res; 2006 Mar; 82(3):512-8. PubMed ID: 16198335
[TBL] [Abstract][Full Text] [Related]
37. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Frank RN; Amin R; Kennedy A; Hohman TC
Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227
[TBL] [Abstract][Full Text] [Related]
38. Application of isoproterenol inhibits diabetic-like changes in the rat retina.
Jiang Y; Walker RJ; Kern TS; Steinle JJ
Exp Eye Res; 2010 Aug; 91(2):171-9. PubMed ID: 20493839
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of iNOS alleviates cognitive deficits and depression in diabetic mice through downregulating the NO/sGC/cGMP/PKG signal pathway.
Zhou XY; Zhang F; Ying CJ; Chen J; Chen L; Dong J; Shi Y; Tang M; Hu XT; Pan ZH; Xu NN; Zheng KY; Tang RX; Song YJ
Behav Brain Res; 2017 Mar; 322(Pt A):70-82. PubMed ID: 28077315
[TBL] [Abstract][Full Text] [Related]
40. BTBR ob/ob mouse model of type 2 diabetes exhibits early loss of retinal function and retinal inflammation followed by late vascular changes.
Lee VK; Hosking BM; Holeniewska J; Kubala EC; Lundh von Leithner P; Gardner PJ; Foxton RH; Shima DT
Diabetologia; 2018 Nov; 61(11):2422-2432. PubMed ID: 30094465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
